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Objective(s): New generation of allergy vaccines is capable of promoting the development of protective 
IgG and blocking the functionality of allergen-specific IgE. We incorporated universal and powerful 
T-cell epitopes from tetanus and diphtheria toxoids (TD epitope) into recombinant Che a 2, the well-
known allergic profilin of Chenopodium album, to determine its immunological properties.
Materials and Methods: The sequence and accordingly the structure of the recombinant Che a 2 was 
altered to generate a hypoallergenic variant (rChe a 2.rs). Moreover, TD epitope was incorporated to 
produce a novel vaccine that was nominated as rChe a 2.rsT.D. The effect of treatment with these variants 
was evaluated on the generation of allergen-specific IgG class, as well as lymphocyte proliferation in 
mice. Moreover, IgE-binding characteristics of the allergic patients’ sera were determined by ELISA 
and proliferation and cytokine production was measured in T-cells. 
Results: ELISA and dot blot revealed strong reduction of the IgE-reactivity of human sera to the 
variants of Che a 2 as compared to the wild-type molecule. Furthermore, Che a 2.rs and Che a 2.rsT.D 
induced much lower levels of IL5 and IL13 secretion from allergic patients’ PBMCs in comparison to 
wild-type Che a 2 protein. In mice, rChe a 2.rsT.D induced high titers of Che a 2-specific IgG antibody 
capable of blocking IgE-binding to rChe a 2 and induced lymphocyte proliferation more potently than 
rChe a 2.rs. 
Conclusion: Collectively, incorporation of T-cell epitopes of tetanus and diphtheria into hypoallergenic 
vaccines can dramatically enhance anti-allergic immune mechanisms, particularly in poor responders.
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Introduction
Allergy, particularly respiratory allergy, is the most 
common health issue worldwide, and its incidence is 
increasing in the developing and industrial countries 
(1-3). Type I allergy is caused by allergic proteins that 
can cross-link FceRI-bound IgE antibodies on effector 
cells such as mast cells and basophils, and subsequently 
lead to releasing of the mediators, including histamine 
and leukotrienes (4). Availability of at least two 
epitopes on the surface of the allergen is crucial for 
successful cross-linking of the membranous FceRI 
molecules of the effector cells. These IgE epitopes can 
be linear or conformational. Linear epitopes contain 
continuous amino acids, while conformational epitopes 
are composed of discontinuous amino acids brought 
together in the three-dimensional structure of the 
protein (5). The allergenic characteristics of the inhaled 
and food allergens mostly depend on their conformation; 
therefore, destruction of the native folding or 
conformation of the allergens will strongly reduce their 
IgE-reactivity (5, 6). Allergen-specific immunotherapy 
(SIT), the only available treatment for allergic disease, 
involves the administration of increasing doses of the 
purified allergen, allergen extracts, or whole food to 
induce desensitization. An effective mechanism of 
desensitization is development of allergen-specific 
protective IgG antibodies (7, 8). However, sometimes 
low protein content and variable quality of the crude 
extracts complicate the clinical application of these 
extracts in SIT (9-12). 
The use of purified allergens or hypoallergenic 
variants of the allergens for SIT removes or reduces 
the problems regarding the content and quality of 
an allergen in crude extract and may also reduce the 
possible side effects during the treatment (13, 14). 
Several strategies may be employed to improve these 
benefits and reduce the possible side effects. One 
strategy involves the incorporation of T-cell-specific 
epitopes in order to induce tolerance in allergen-specific 
T-cells (15, 16). A novel approach is to genetically alter 
the amino acid sequence of the allergen by making 
mutations, deletion, or inversion in the DNA sequence to 
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generate a hypoallergenic variant (17-19). Manipulation 
of the allergen to generate hypoallergenic vaccine 
may remove CD4+ T cell epitopes that are essential for 
T-cell-dependent antibody responses. In this case, the 
hypoallergen may induce production of allergen-specific 
IgG or other T cell-dependent protective immunological 
responses. Therefore, the concern for the abolishment 
of T-cell epitopes complicates vaccine design via genetic 
engineering strategies (19, 20).
The current study presents a strategy to enhance the 
potency of the recombinant-hypoallergenic vaccines by 
incorporating two strong and universal T helper cell 
(Th) epitopes from tetanus (T 830-844) and diphtheria 
toxoid (D 331-345) (21, 22) linked to the internal 
cathepsin cleavage site, in order to further enhance the 
activation and response of the T cells. We believe that 
this approach will alleviate concerns and limitations 
related to the potential loss of allergen-specific T-cell 
epitopes in genetically engineered vaccines. 
In the current study, a genetically modified 
hypoallergenic variant of the profilin from Chenopodium 
album (Che a 2), which is a highly cross-reactive and 
clinically relevant pan-allergen in pollens of plants, 
weeds, and grasses (23-25), was generated according 
to the tail-to-head exchanging strategy. Following 
the recombination of the N-terminal and C-terminal 
fragments of the allergen, as described by Westritschnig 
et al. (26), TD epitopes were added on the C-terminal 
end of the protein. The reconstructed allergen was then 
used to test for IgE-binding and to treat peripheral blood 
mononuclear cells from allergic patients. Our study 
demonstrates that the T cells recognize TD epitopes 
incorporated into hypoallergenic Che a 2.rs (Che a 
2.rsT.D), which may lead to altering the immune response 
and boosting IgG production against profilin.
Materials and Methods
Molecular modeling of the Che a 2 allergen and 
designing hypoallergenic Che a 2 containing T.D 
epitope 
The ribbon structure of Che a 2 (Genbank accession 
No: AY082337.1) was constructed by a fully automated 
protein structure homology-modeling server. The 
profilin from Hevea brasiliensis (27), Birch (28), and 
Arabidopsis thaliana (29) was employed to generate a 
model for profilin from C. album, Che a 2. The quality 
of the constructed model was assessed by the QMEAN 
server.Considering previously identified IgE epitopes on 
profilin (26), Che a 2-encoding cDNA was reconstructed 
through tail-to-head recombination of the P1 peptide 
at N-terminal and P5 at C-terminal peptide of Che a 2 
to generate a hypoallergenic variant which was termed 
as Che a 2.rs. Moreover, T-cell epitopes including TD 
epitopes with cathepsin cleavage sites were added to 
the C-terminal end of Che a 2.rs, resulting in Che a 2.rsT.D 
construct (Figure 1).
Expression and purification of r.Che a 2.rs and r.Che 
a 2.rsT.D  
Che a 2.rs (399 bp) and Che a 2.rsT.D (507 bp) cDNAs 
(codons optimized for expression in Escherichia coli) 
were chemically synthesized (Pepmic Co, China), 
and inserted into the Nde1/XhoI sites of pET21-a 
(Novagen, USA) so that the 6-His-tagged region located 
at C-terminus. The inserted nucleotide sequence was 
confirmed by restriction enzyme digestion and by 
means of automated DNA sequencing. Then E. coli BL21 
cells (Novagen, USA) were transformed by the construct 
and selected on Luria-Bertani (LB) plates containing 
100 µg/ml of ampicillin. A typical colony was picked 
and after overnight culture at 37 °C, inoculated into 300 
ml LB medium containing 100 µg/ml of ampicillin and 
incubated at 37 °C until the absorbance reached 0.5 
at 600 nm. Then, the expression of the recombinant 
proteins was induced by adding 1 mM isopropyl-
thiogalactopyranoside (IPTG) for approximately 
four hours. Finally, bacterial cells were harvested by 
centrifugation at 4000 rpm for 10 min, and the pellet 
was re-suspended in 5 ml of lysis buffer (100 mM/l 
NaH2PO4; pH 7.0, 10 mM Tris-Cl, 150 mM NaCl), and 
the bacterial cells were disrupted by ultrasonication 
five times at 22 kHz at 20-sec intervals on ice. Both 
   
 
 
 
 
 
 
Figure 1. Ribbon diagram and linear depiction of Che a 2, Che a 2.rs, and Che a 2.rsT.D
a) The ribbon representation of the structure of Che a 2 predicted by Swiss model. b) Linear representation of wild-type Che a 2, restructured 
Che a 2 (Che a 2.rs) and Che a 2.rs fused from C-terminus to T-cell epitopes from tetanus and diphtheria toxoid (Che a 2.rsT.D). CS represents the 
cathepsin cleavage site (PMGLP)
Iran J Basic Med Sci, Vol. 23, No. 5, May 2020
Ghasemi et al. Enhancement of the immune response against allergens 
638
proteins were expressed as insoluble inclusion bodies 
and existed in the pellet fraction. The pellets were 
solubilized (6 M urea, 100 mM NaH2PO4, 10 mM Tris-Cl; 
pH 8) for two hours at 37 °C. Insoluble proteins were 
removed by centrifugation (10000 rpm for 15 min at 
4 °C) and the urea concentration was reduced to 2 mM 
with stepwise dialysis in order to allow refolding of the 
protein. The 6-His-tagged recombinant proteins were 
purified by nickel affinity chromatography (Ni-NTA 
agarose) (Thermo Fisher Scientific, USA) according to 
the manufacturer’s instructions, and dialyzed against 
50 mM NaH2PO4, pH 7.  Purified rChe a 2 protein (30) 
containing Trx-tag was kindly gifted by Dr. A. Varasteh 
(Bu-Ali Research Center, Mashhad, Iran), and its Trx-tag 
was removed. 
Allergic patients
Sera from 15 C. album-allergic patients (9 males and 6 
females) with the mean age of 30.13 years were utilized 
to characterize the designed hypoallergenic molecules 
(Table 1). The mean specific IgE of the patients was 
7.74±1.29 IU/ml for C. album as determined by enzyme 
allegro sorbent test (EAST) and all of them had a clinical 
history of allergy and positive skin prick test for C. album. 
The obtained serum samples were investigated for the 
level of Che a 2-specific IgE (31) and recombinant Che a 
2 (rChe a 2) protein. Serum samples from non-allergenic 
individuals (n:7) were used as control. The Ethics 
Committee of the Persian Gulf Biomedical Sciences 
Research Institute approved the study methods, and all 
participants signed the informed consent forms before 
starting the project.
Evaluation of IgE-binding capacity of recombinant 
r.Che a 2, r.Che a 2-rs., and r.Che a 2-rsT.D with indirect 
ELISA and dot blot
IgE-reactivity of recombinant proteins, r.Che a 2, r.Che 
a 2-rs, and r.Che a 2-rsT.D was determined by an in-house 
developed indirect ELISA and dot blot assay. Indirect 
ELISA was performed as previously described (32). 
Briefly, recombinant proteins (2 μg/well) were coated 
into the wells and then the wells were blocked with 2% 
bovine serum albumin (BSA, Sigma, MO, USA). Wells 
were exposed to 1:5 diluted sera of patients with allergy 
to rChe a 2 (n:15) or non-allergenic individuals’ sera 
(n:7) and incubated with 1:2000 diluted biotin-labeled 
anti-human IgE (Abcam, UK). Wells were incubated 
for one hour with 1:30000 diluted HRP-conjugated 
streptavidin (Sigma, MO, USA). After addition of TMB/
H2O2 chromogen/substrate (Sigma, MO, USA), the plates 
were incubated in the dark for 15 min. The reaction 
was stopped by addition of 100 μl of 2 N H2SO4. Finally, 
the optical density (OD) of the wells was measured at 
450/630 nm. 
Dot blot was performed as previously described (33). 
Briefly, 2 μg of recombinant proteins were coated on 
nitrocellulose membrane disks (5 mm diameter) (Sigma, 
MO, USA), blocked with 2% BSA and incubated overnight 
with 1/5 diluted sera of patients with allergy (n: 10). 
After incubation with 1:2000 diluted biotin-labeled anti-
human IgE (Abcam, UK) and subsequently with 1:30000 
diluted HRP conjugated streptavidin (Sigma, MO, USA) 
for 1 hr at room temperature, immuno-reactivity of 
the coated disks was revealed by a chemiluminescent 
substrate (Amersham, GE Healthcare Life Science) in a 
gel documentation system (G:BOX Chemi XX9 gel doc 
system, UK). 
Immunization of mice and evaluation of IgG antibody 
response
Six groups of seven-week-old female BALB/c mice 
(5 mice per group) were either subcutaneously pre-
vaccinated with DPT vaccine or left untreated. Three 
weeks later, mice were immunized three times (in two-
weeks intervals) with 15 μg of r.Che a 2, r.Che a 2.rs, 
or r.Che a 2.rsT.D pre-adsorbed on aluminum hydroxide 
gel, and blood samples were collected from the tail vein 
after each immunization and two weeks after the last 
immunization. To investigate whether incorporation 
of strong T-cell epitopes in vaccines could enhance 
a protective antibody response under sub-optimal 
vaccine conditions, such as low doses of vaccine in 
poor responders such as aged mice (10 months old), 
we performed another experiment. For this purpose, 4 
groups of nine-month-old female BALB/c mice (five mice 
per group) were either pre-vaccinated with DPT vaccine 
and/or left unvaccinated; and 28 days later, the two 
groups were immunized with 1 μg of r.Che a 2, r.Che a 2.rs, 
or r.Che a 2.rsT.D pre-adsorbed on aluminum hydroxide. 
Sera were obtained 0, 7, and 14 days post-immunization 
via the tail vein. The production of rChe a 2-specific IgG 
in immunized mice was assessed by indirect ELISA. The 
microplate wells were coated with rChe a 2 (2 µg/well) 
and incubated with 1:500 diluted immunized mice sera. 
After the washing step, wells were probed with 1:2000 
diluted HRP-conjugated goat anti-mouse IgG (Abcam, 
UK) for two hours at room temperature. Finally, TMB/
H2O2 chromogen/substrate (Sigma, MO, USA) was added 
and OD of r.Che a 2-specific IgG response was measured 
at 450/630 nm. The corresponding pre-immunized mice 
Table1. Demographic and serological data of Chenopodium album-
allergic patients
 
1 
 
 
 
Patients Age  (years) Gender 
C. album Specific IgE  
(IU/ml) Symptoms 
1 24 M 8.4 As, Rc 
2 32 M 9.8 Rc 
3 18 F 7.4 R 
4 25 M 8.3 RC 
5 38 F 9.4 R 
6 32 F 6.2 R, AS 
7 40 F 8.2 RC 
8 35 M 4.5 R 
9 26 M 7.8 R 
10 37 M 6.6 Rc, As 
11 23 F 8.4 Rc 
12 21 M 7.3 Rc 
13 36 F 8.5 Rc 
14 27 M 7.9 R 
15 31 M 7.4 R 
 
 
 
 
Rc: rhinoconjunctivitis; R: rhinitis; As: Asthma; M: male; F: female
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sera were used as negative control in this experiment. 
Antibody titer was defined as half-maximal binding 
that is reciprocal to dilution presented at half-maximal 
optimal density (OD50).
Competitive inhibition ELISA (ciELISA) for 
determination of the allergic patients’ IgE-binding 
capacity to r.Che a 2 
Inhibition of allergic patients’ IgE-binding capacity 
to rChe a 2 was determined using immunized mice sera 
by competitive inhibition ELISA (ciELISA). ELISA wells 
were coated with r.Che a 2 (1 μg/well), and incubated 
with serum mixtures comprising decreasing amounts 
of sera from immunized mice (final dilution ranging 
from 1:50 to 1:50000) as the competitive antibody and 
pooled sera (final dilution 1:5) from allergic patients (n: 
10) according to the following combination:
A) No competitor: 50 µl of 1:2.5 dilution of patients 
pooled sera+50 µl of 1:25 dilution of non-immunized 
mice sera; 
B) 1:50-diluted competitor: 50 µl of 1:2.5 dilution of 
patients pooled sera+50 µl of 1:25 dilution of immunized 
mice sera; 
C) 1:100-diluted competitor: 50 µl of 1:2.5 dilution of 
patients pooled sera+50 µl of 1:50 dilution of immunized 
mice sera; 
D) 1:500-diluted competitor: 50 µl of 1:2.5 dilution 
of patients pooled sera+50 µl of 1:250 dilution of 
immunized mice sera;
E) 1:5000 diluted competitor: 50 µl of 1:2.5 dilution 
of patients pooled sera+50 µl of 1:2500 dilution of 
immunized mice sera; 
F) 1:50000 diluted competitor: 50 µl of 1:2.5 dilution 
of patients pooled sera+50 µl of 1:25000 dilution of 
immunized mice sera
After the washing steps, wells were incubated with 
1:2000 diluted biotin-labeled anti-human IgE (Abcam, 
UK), and subsequently, with 1:30000 diluted HRP 
conjugated streptavidin (Sigma, MO, USA) for one hour 
at RT. The percentage of inhibition was calculated as 
follows: (ODz –ODc / ODz)×100.
Where ODz and ODc represent the optical density of 
samples without competitor (zero competitor), and 
optical density of the sample with competitor, respectively. 
Cell Proliferation assay (MTT) and cytokine response 
of PBMCs
PBMCs were isolated from heparinized whole blood 
samples of five patients with clinical history and typical 
symptoms (rhinitis, conjunctivitis) for allergy to pollens 
who had a positive prick test for C. album and had specific 
IgE to Che a 2 (mean age:42 years) by Ficoll density 
gradient centrifugation. Splenocytes were stimulated 
with r.Che a 2, r.Che a 2.rs, or r.Che a 2.rsT.D, and the 
proliferation of the cells was assessed using Vybrant® 
MTT Cell Proliferation Assay Kit (Thermo Scientific, 
USA) according to the manufacturer’s instructions. 
For this purpose, PBMCs were incubated in 48-well 
microplates in RPMI 1640 supplemented with fetal 
bovine serum, penicillin (100 U/ml), and streptomycin 
(100 μg/ml) (Sigma, MO, USA) at the density of 1×106 
cell/well. The cells were stimulated with r.Che a 2, 
r.Che a 2.rs, r.Che a 2.rsT.D (10 ng/μl), or IL-2 (5 U/well, 
Roche Diagnostics, Rotkreuz, Switzerland) as a positive 
control. After seven days, lymphocyte proliferation 
was determined and presented as proliferation index 
(OD570 of stimulating cells/mean OD570 of control cells). 
Pro-allergenic cytokines, including IL-4, IL-5, and IL-13 
were quantified in the supernatant of PBMC cultures 
stimulated with r.Che a 2, r.Che a 2.rs, and r.Che a 2.rsTD 
using RayBiotech ELISA kit (RayBiotech, Inc.).
Results
Che a 2.rsT.D was designed according to tail-to-head 
recombination strategy
The ribbon structure of Che a 2 and the restructured 
constructs are shown in Figure 1.  In this figure, the 
color of the ribbon diagram in Panel A corresponds to 
the linear forms in panel B, depicting the changes made 
to native Che a 2 to produce the hypoallergenic variant 
(Che a 2rs), as well as the location of the incorporated 
T-cell epitopes and cathepsin cleavage sites in Che a 
2rsTD. P1, an unordered loop at N-terminal end, and 
alpha-helical P5 peptides at the C-terminal end are the 
known IgE-binding sites in profilin (26). 
Expression, purification, and IgE-reactivity of Che a 2, 
Che a 2.rs, and Che a 2.rsT.D 
The recombinant proteins were successfully 
expressed in E. coli, purified by means of metal affinity 
chromatography and subjected to SDS-PAGE analysis 
(Figure 2). As shown in Figure 3, typical protein band 
could be observed on the coomassie blue-stained SDS-
PAGE slabs, in which the band with the molecular 
weight of approximately 15.6 kDa corresponds to Che 
a 2.rs (containing His-tag, two added amino acids by 
xho1 site and the initiator methionine), and the bigger 
protein band (approximately 19.6 kDa) corresponds to 
Che a 2.rsT.D (containing His-tag, two added amino acids 
by xho1 site and the initiator methionine).
The IgE-reactivity of r.Che a 2, r.Che a 2.rs, or r.Che a 
2.rsT.D in patients with allergy to r.Che 2 was evaluated by 
dot blot and indirect ELISA (Figure 3). Dot blot results 
demonstrated a significant reduction in IgE-reactivity 
  
 
 
 
 
 
Figure 2. SDS-PAGE analysis of purified rChe a 2, Che a 2.rs, and Che 
a 2.rsT.D
Expressed proteins rChe a 2 (15.6 kDa), rChe a 2.rs (15.6 kDa), and 
rChe a 2.rsT.D (19.5 kDa) were loaded on 15% polyacrylamide SDS-
PAGE gel and their molecular weights were evaluated using low 
molecular weight protein marker. Symbols: Che a 2.rs, restructured 
Che a 2; Che a 2.rsT.D, restructured Che a 2 fused to CD4 epitope of 
diphtheria and tetanus toxoid; rChe a 2, recombinant Che a 2
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of both restructured variants including r.Che a 2.rs and 
r.Che a 2.rsT.D for all 10 patients tested (Figure 3a). IgE-
binding ELISA results with serum from 15 patients also 
confirmed a considerable reduction in the IgE-binding 
capacity of r.Che a 2.rs and r.Che a 2.rsT.D compared with 
r.Che a 2 (Figure 3b).  
Che a 2.rsT.D produces Che a 2-specific IgG more 
potently than Che a 2.rs in mice
The production of Che a 2-specific IgG antibody was 
compared in mice sera after immunization with r.Che a 
2, Che a 2.rs, or Che a 2.rsT.D, using ELISA. A high-titer 
of Che a 2-specific IgG antibody was observed in mice 
immunized with the vaccine containing universal CD4+ 
T cell epitope from tetanus and diphtheria toxoid (Che 
a 2.rsT.D) compared with those immunized with rChe a 2 
or Che a 2.rs (Figure 4). Furthermore, pre-vaccination of 
mice with DPT vaccine-induced a rapid and significant 
increase of the antibody response in mice vaccinated 
with Che a 2.rsT.D.
In order to determine if the incorporation of the 
universal CD4+ T-Cell epitopes from tetanus and 
diphtheria toxoid could also enhance the antibody 
response under sub-optimal vaccination conditions, 
including poor responders (aged mice), we also 
immunized some old mice with very low doses of 
the antigen. Results indicated that the only vaccine 
containing the universal CD4+ epitopes from tetanus 
and diphtheria toxoid, r.Che a 2.rsT.D, could significantly 
boost Che a 2–specific IgG response in aged mice. The 
level of Che a 2-specific IgG antibody titer was higher in 
mice immunized with r.Che a 2.rsT.D, so that it was five 
times greater than those mice immunized with r.Che a 
2.rs (Figure 5), and this response became 12.21 times 
greater in mice pre-vaccinated with the DPT vaccine, 
 
 
 
 
 
Figure 3. The IgE-reactivity of rChe a 2, rChe a 2.rs, and rChe a 2.rsT.D 
a) Disk-blotted rChe a 2, rChe a 2.rs, and rChe a 2.rsT.D were evaluated 
by Che 2-sensitive patients’ sera (n=10). Serum of only one patient 
(No.5) showed very low IgE-reactivity with restructured variants of 
Che a2 (rChe a 2.rs and rChe a 2.rsT.D), too. b)  Comparison of IgE-
reactivity of rChe a 2, rChe a 2.rs, and rChe a 2.rsT.D with sera from 
rChe a 2-sensitive patients (n=15) and healthy individuals (n=7). Data 
shows the mean+SD of triplicate wells per group
  
 
 
 
 
 
 
Figure 4. Evaluation of Che a 2-specific IgG antibody titer in young immunized mice by indirect ELISA
BALB/c mice (8 weeks) were pre-vaccinated with DPT vaccine or left unvaccinated. After 3 weeks, mice (five mice per group) were immunized 
three times (at 0, 14, 28 days) with rChe a 2, rChe a 2.rs, or rChe a 2.rsT.D and the level specific IgG antibody titer against recombinant Che a 2 (rChe 
a 2) were evaluated for each time point. A significance value (P-value) determined between antibody titer in mice immunized with rChe a 2.rsT.D 
(prevaccinated with DPT vaccine or without prevaccination) and Che a 2.rs. Symbols: *, P-value ≤0.05; **, P-value ≤0.01;***, P-value ≤0.005
  
 
Figure 5. Evaluation of Che a 2-specific IgG antibody titer under 
limiting condition. 
Four groups of nine-month-old female BALB/c mice (five mice per 
group)  were pre-vaccinated with the DPT vaccine or left unvaccinated, 
after 4 weeks, mice were immunized with sub-optimal dose (1 μg/ml) 
of rChe a 2.rs or rChe a 2.rsT.D, and immunogenicity of antigens was 
assessed at 0, 7, and 14 days after vaccination. A significant difference 
was found between the titer of the antibody in mice immunized with 
Che a 2.rsT.D (primed with DPT vaccine or not primed) and Che a 2.rs. 
Symbols: *, P-value ≤0.05; **, P-value ≤0.01;***, P-value ≤0.005
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while the other vaccine elicited significantly lower 
antibody responses in mice.
Incorporation of TD epitope in Che a 2.rs enhances 
production of IgG, capable of blocking IgE-binding 
The percentage of inhibition of IgE-binding to rChe a 
2 in immunized mice sera (containing Che a 2-specific 
IgG) was measured with ciELISA. The results showed 
that sera from mice immunized with r.Che a 2.rsT.D 
exhibited greater inhibitory activity against IgE-binding 
to rChe a 2 in comparison to sera from mice immunized 
with r.Che a 2.rs (Figures 6 a, b). Prevaccination of mice 
with DPT vaccine-induced higher inhibitory activity 
than sera from mice immunized with r.Che a 2.rsTD 
that were not prevaccinated. The mean percentages of 
IgE-binding inhibition to rChe a 2 by anti-r.Che a 2.rsT.D 
antibody from mice pre-vaccinated with DPT vaccine 
were 1.67- and 1.35-fold greater than sera from mice 
vaccinated with r.Che a 2.rs  in mouse sera with  1:5000 
to 1:50000 dilutions, respectively. Evaluation of blocking 
IgG response in old mice (10 months) immunized 
with low antigen dose revealed that the production of 
blocking IgG antibody in mice immunized with r.Che a 
2.rs was very low, while r.Che a 2.rsT.D enhances blocking 
IgG production considerably, even under sub-optimal 
vaccination conditions. The mean percentages of 
inhibition of IgE-binding to Che a 2 by sera from mice 
immunized with r.Che a 2.rsT.D or r.Che a 2.rs were 50 % 
or 13 %, respectively.
Incorporated T-cell epitopes from tetanus and 
diphtheria toxins are recognized by lymphocytes   
The MTT proliferation assay was used to determine 
if the incorporation of T-cell epitopes from tetanus 
and diphtheria toxoids into the protein vaccine can 
increase the proliferation of the lymphocytes obtained 
from patients with allergy to Che a 2. The incorporated 
T-cell epitopes from tetanus and diphtheria toxoids 
into Che a 2.rsT.D vaccine increased the proliferation of 
lymphocytes more potently than r.Che a 2.rs. Evaluation 
of pro-allergenic cytokines from stimulated PBMC 
revealed that r.Che a 2.rs- and r.Che a 2.rsT.D-stimulated 
PBMCs secreted significantly lower levels of IL-5 and IL-
13, compared with those stimulated with r.Che a 2.
Discussion
The current study provides evidence that incorporation 
of two powerful and universal T-cell epitopes from 
tetanus and diphtheria toxoids into a hypoallergenic 
vaccine could potentially improve protective allergen-
specific IgG response, which may be important in allergy 
immunotherapy (34, 35). Disruption of linear- and 
conformational-type IgE epitopes either by deletion, 
inversion, or a mosaic restructuring are the most well-
known strategies to generate hypoallergenic derivatives 
from allergens (19, 36). However, these strategies 
might destroy some T-cell epitopes and subsequently 
reduce vaccine-induced antibody response, as well as 
limit the population coverage of vaccine. It seems that 
the incorporation of exogenous universal T helper cell 
epitopes from tetanus (T830-844) and diphtheria (D331-
345) may increase hypoallergen-induced IgG response, 
and remove problems regarding the abolishment of 
allergen-specific T-cell epitopes. Previous experiments 
demonstrated that T-cell T830-844 and  D331-345 
epitopes bind to various MHC class II  alleles that result in 
the employment of CD4+ T helper cells involved in B-cell 
maturation. Also, the presence of pre-existing CD4+ cell 
memory to the mentioned TD epitopes in tetanus and 
diphtheria vaccinated individuals can induce a rapid 
and robust antibody response against the TD-epitope-
fused allergen (21, 34, 35, 37, 38). In the current study, 
we designed a hypoallergenic variant for profilin from C. 
album (Che a 2), termed r.Che a 2.rs, in accordance with 
the strategy used to generate hypoallergenic Phl p 12 
and profilin from timothy grass (26). Che a 2.rs exhibited 
significantly diminished IgE-binding compared with 
r.Che a 2, which is similar to what is observed with the 
hypoallergenic derivative of  Phl p 12 generated by 
Westritschnig et al. (26), and confirms the crucial role 
of conformational-type IgE epitope in the allergenic 
activity of profilins. Incorporation of T830-844 and 
D331-345 epitopes in the designed hypoallergenic 
vaccine significantly enhanced IgG production in mice, 
capable of inhibiting IgE-binding from the serum of 
allergic patients to Che a 2. This could be due to the 
stimulation of allergen-specific IgG antibody-producing 
B-cells by TD epitopes-specific T-cells. In addition, Che 
 
 
 
Figure 6. Competitive inhibition ELISA (ciELISA) for measurement of 
rChe a 2-specific IgE-inhibition by IgG antibody in immunized mice 
sera
a) ELISA wells coated with rChe a 2 were incubated with a mixture 
of sera composed of 1:5-diluted pooled sera from rChe a 2-sensitive 
patients (n=10) and various dilutions of sera (1:50, 1:100, 1:500, 
1:5000, and 1:50000) from immunized mice (n=5). IgE-binding 
capacity of rChe a 2 was measured at 450/630 nm. b) The figure 
shows the percentage of inhibition of IgE-binding to rChe a 2 by 
various dilutions of anti-rChe a 2, anti-rChe a 2.rs, or anti-rChe a 2.rsT.D 
antibodies. * represents P-value<0.05
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a 2.rsT.D dramatically induced a rapid and robust IgG 
response in mice prevaccinated with DPT compared 
with the non-prevaccinated ones. This can be the 
reason behind the pre-existing TD epitopes-specific 
T-cell memory in mice prevaccinated with DPT. In 
various experiments, T830-844 was fused to antigen 
in order to recruit T-cell ‘help’ to B-cell producing 
antibodies, such as MAG-Tn3 therapeutic vaccine that 
is under phase 1 clinical trial. MAG-Tn3 contains α-D-
N-acetylgalactosamine (Tn antigen as B-cell epitope) 
conjugated to T830-844 epitope (35). Ahlborg et al. 
(34) demonstrated that linkage of T830-844 epitope 
to C-terminal region, derived from merozoite surface 
protein 1 (MSP119), induced protective IgG response 
against malaria in mice. Fraser et al. (21) demonstrated 
that a dimeric MHC class II binding peptide including 
T830-844 epitope and D331-345 linked with an internal 
cathepsin cleavage site could improve population 
coverage and induce greater IgG response compared 
with individual peptides. The T.D epitopes induced a 
memory recall in all PBMC obtained from humans, and 
conjugation of TD epitope to nicotine nanoparticles 
produced rapid and robust anti-nicotine antibody. The 
immunogenicity assessment of Che a 2.rsT.D and Che a 
2.rs in suboptimal immunization conditions, including 
aged mice immunized with low-dose vaccine revealed 
that TD epitopes could enhance the immunogenicity 
of the vaccine even in poor responders. According to 
the increasing rates of allergies in elderly people (39, 
40), and decreasing naive T-cells and naive B-cells with 
aging, fusion of a universal TD epitope in hypoallergenic 
vaccines may be a potential method to enhance 
immunogenicity of hypoallergenic vaccines in elderly 
patients by recruiting more T-cell and pre-existing T-cell 
in individuals that received the DPT vaccine. As shown 
in Figure 7, we found that lymphocytes stimulated with 
the Che a 2rsTD show comparatively high capacity in 
the proliferation of lymphocytes obtained from patients 
with allergy and a decrease in allergy-inducing cytokine 
secretion.
Conclusion
Development of allergen-specific IgG is one of the 
purposes and signs of successful specific immunotherapy. 
The current study demonstrates that incorporation 
of powerful and universal epitopes from tetanus and 
diphtheria toxoids in a hypoallergenic variant of an 
allergen vaccine could improve protective antibody 
response, even under suboptimal immunization 
condition. This study also provides an efficient strategy 
for generation of blocking antibody responses against 
allergens, even in suboptimal immunization conditions.
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